Regeneron Launches New Human Genetics Initiative

               Regeneron Launches New Human Genetics Initiative

PR Newswire

TARRYTOWN, N.Y., Jan. 13, 2014

TARRYTOWN, N.Y., Jan. 13, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that it has launched a new human genetics
initiative via a new wholly owned subsidiary, the Regeneron Genetics Center
LLC (RGC). The objective of the RGC is to expand the use of human genetics
for defining disease targets and improving the drug development process. The
RGC will pursue both large population-based efforts as well as family-based
approaches.

Central to the work of the RGC will be a collaboration with the Geisinger
Health System of Pennsylvania, announced in a separate press release today. A
collaboration is also in place with the National Human Genome Research
Institute of the National Institutes of Health, and the Center intends to
develop relationships with other academic, government, and integrated medical
systems.

"Regeneron has always believed in the power of genetics to help shape our
understanding of disease and to guide development of novel therapeutics.
However, there have been major limitations that have prevented optimal
utilization of human genetics at a large-scale," said George D. Yancopoulos,
M.D., Ph.D., Chief Scientific Officer and President, Regeneron Laboratories.
"We believe that we can now address these limitations, and that now is the
time to increase our investment in human genetics. Over the last year we have
been building a world-class facility and top-notch team to carry out
large-scale sequencing, and today we are announcing that our Regeneron
Genetics Center is operational. We have also started to engage in
collaborations that we believe will enable the kinds of genetics discoveries
that will lead to better patient care, insights into which patients might best
respond to investigational treatments, and leads for new disease targets to
develop novel therapeutics. The relationship with Geisinger is a cornerstone
of the effort we are building, which we believe can advance the goals of human
genetics research and personalized medicine."

Andrew J. Murphy, Ph.D., Senior Vice President, Research, Regeneron
Laboratories, added, "One of the unique aspects of the Regeneron human
genetics research effort is our ability to validate putative disease-gene
associations using our proprietary VelociGene^® technology. Moreover, our
VelocImmune^® technology has already proven itself ideal for developing novel
therapeutics to disease targets defined using human genetics. The RGC is an
important investment in large-scale genetic research that we believe
represents a powerful integrated approach that we hope will go all the way
from gene discoveries to novel therapeutics."

Over the last year, Regeneron has built a new facility and recruited key
members of the RGC team, including John Overton, Ph.D., former Associate
Director of the Yale Center for Genome Analysis, who will be leading the
center's sequencing effort, and Jeffrey Reid, Ph.D., formerly Assistant
Professor at the Human Genome Sequencing Center at Baylor College of Medicine,
who will lead the informatics group. Aris Baras, M.D., Director, R&D
Initiatives, who with other internal leaders helped launch the program, will
serve as Deputy Head of the RGC. Recruiting continues for a variety of
specialized positions, including heads of our analytical and translational
genetics efforts.

"I am thrilled to be joining Regeneron as we initiate this new scientific
research effort," said Dr. Overton. "Regeneron's strong commitment to the
success of this project, combined with its entrepreneurial spirit and
well-established expertise in basic research and mouse genetics, form a
foundation we feel will lead to significant advances in our understanding of
the fundamental etiology of diseases, drug development, and, ultimately, in
patient care."

"Bringing large-scale human genome sequencing together with Regeneron's
world-class mouse genetics program has potential to identify validated targets
for drug discovery and make clinically-relevant genetic discoveries that,
through our collaborations, can speed up the translation from science to
medicine and accelerate the pace of the genomic medicine revolution," said Dr.
Reid.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition, and has product candidates in development in other
areas of high unmet medical need, including

hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic
dermatitis. For additional information about the company, please visit
www.regeneron.com.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of
Regeneron, and actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs
now underway or planned including without limitation the planned genetic
research collaboration with Geisinger Health System, Regeneron's translational
research and functional biology capabilities, and the planned expansion in the
use of human genetics in Regeneron's research process; unforeseen safety
issues resulting from the administration of products and product candidates in
patients; the likelihood and timing of possible regulatory approval and
commercial launch of Regeneron's late-stage product candidates; ongoing
regulatory obligations and oversight impacting Regeneron's research and
clinical programs and business, including those relating to patient privacy;
determinations by regulatory and administrative governmental authorities which
may delay or restrict Regeneron's ability to continue to develop or
commercialize Regeneron's products and product candidates; competing drugs and
product candidates that may be superior to Regeneron's products and product
candidates; uncertainty of market acceptance and commercial success of
Regeneron's products and product candidates; the ability of Regeneron to
manufacture and manage supply chains for multiple products and product
candidates; coverage and reimbursement determinations by third-party payers,
including

Medicare and Medicaid; unanticipated expenses; the costs of developing,
producing, and selling products; the ability of Regeneron to meet any of its
sales or other financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential for any
license or collaboration agreement, including Regeneron's agreements with
Sanofi and Bayer HealthCare, to be cancelled or terminated without any further
product success; and risks associated with third party intellectual property
and pending or future litigation relating thereto. A more complete
description of these and other material risks can be found in Regeneron's
filings with the United States Securities and Exchange Commission, including
its Form 10-K for the year ended December 31, 2012 and its Form 10-Q for the
quarter ended September 30, 2013. The reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does not undertake
any obligation to update publicly any forward-looking statement, including
without limitation any financial projection or guidance, whether as a result
of new information, future events, or otherwise.

Your Investor Relations Contact at Regeneron:
Manisha Narasimhan, Ph.D. Tel. 914.847.5126
E-Mail: manisha.narasimhan@regeneron.com

Your Media Contact at Regeneron:
Peter Dworkin, Tel. 914.847.7640
E-Mail: peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com
 
Press spacebar to pause and continue. Press esc to stop.